Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Orkla ASA: Mandatory notification of trade – primary insiders

Jaan Ivar Semlitsch, President & CEO of Orkla, has today bought 12,500 shares at an average price of NOK 86.01 per share. Following this transaction, Semlitsch and related parties own 40,000 shares in Orkla. Orkla ASAOslo, 18 November 2019Ref.:Investor RelationsElise HeidenreichTel.: +47 951 41 147 Please click here  if you wish to terminate your subscription to press releases from Orkla. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Dampskibsselskabet NORDEN A/S – Weekly report on share buy-back

ANNOUNCEMENT NO. 19 - 18 NOVEMBER 2019 On 7 November 2019, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 7 November 2019 up to and including no later than 28 February 2020. For details please see announcement no. 17 of 6 November 2019. Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 10 million (approximately DKK 67 million).

RhoVac reports interim results on immunological response with RV001

Today, 18th November 2019, RhoVac AB ("RhoVac") reports interim results from ongoing immunological studies at University of Tübingen, Germany concluding that treatment with RV001 can activate CD4+ T-cells and also CD8+ T-cells.In July 2019 RhoVac published results on the follow-up phase of the phase I/II clinical study and in relation to the immunological response it could be concluded that 18 patients showing significant treatment related immunological response at completion of treatment. All 18 patients still showed significant response at 3-, 6- and 9-months follow-up. At the 12-months

H2PS-5 has been approved by EBRD (European Bank of Reconstruction & Development)

Helbio today announced that H2PS-5 (its small CHP system) has been approved by EBRD (European Bank of Reconstruction & Development) and has been listed into the catalogue of EBRD for CHPs.EBRD provides bridge finance program for our product, to support financially the end user by covering a percentage (usually 20%) of the product price. Further information may be found at: https://ts.ebrdgeff.com/gtc-en/catalog/product/view/id/13663/s/1573475148-7439-h2ps-5/  For further information, please contact CEO Christopher Tornblom, phone +44 7827 509544 or e-mail info@metacon.se About

UIE Third Quarter Report 2019

UIE’s net profit in the first nine months of 2019 amounted to USD 40.5 million, which is 27% lower than the result reported in the first nine months of 2018. UIE’s share of UP’s net profit was USD 23.5 million, which is a decrease of 31% compared to the first nine months of 2018. The fair value of the investment in Schörling increased by USD 16.7 million in the first nine months of 2019 compared to an increase of USD 20.6 million in the first nine months of 2018.

Reminder: Invitation to DNB's Capital Markets Day - 20 November 2019

DNB is pleased to invite you to the Group's Capital Markets Day. Date: Wednesday 20 November 2019Time: 12:00 pm - 2:30 pm GMT. Registration and lunch from 11:00 am - 12:00 pm GMT Location: Hotel Claridge's, Brook Street, Mayfair, London W1K 4HR, England We will present the financial targets for the next period. Topics will include the Group's operating environment, ROE, digitalisation, asset quality and capital. Speakers at the CMD will be:- Kjerstin R. Braathen, CEO- Ottar Ertzeid, CFO- Harald Serck-Hanssen, Group EVP Corporate Banking- Ingjerd Blekeli Spiten, Group

BrainCool AB (publ) – A new clinical study with RhinoChill™ show statistically significant results that early cooling leads to improved survival and neurological function of cardiac arrest patients

The clinical study, presented at the American Heart meeting this weekend, was a prospectively analysis of collected data from the PRINCESS trial. It is expected to be published in a high rank medical journal this winter. The objective of the study was to investigate investigate the association between time to initiate cooling and neurological intact survival in patients with out-of-hospital cardiac arrest. An early treatment group was defined as patients randomized by the EMS < 20 minutes from the time of the cardiac arrest. Time to randomization was used a proxy measurement for time to

C-RAD opens a new office in Shanghai, China

C-RAD is pleased to announce the opening of a new office in the high-tech district in Shanghai, China. C-RAD’s goal involves being closer to the customers and increasing customer service. C-RAD’s new office in Shanghai will allow us to both, host our growing local organization and to invite customers to present C-RAD and our technology in our own facility. “I am proud to set up our branch office in Shanghai.” says Kurt Wang, President C-RAD China, “C-RAD is committed to provide cutting edge surface tracking solution to our customers and an excellent service around the product. Among

Itiviti announces partnership with CMS for the Consolidated Audit Trail (CAT) Reporting

New York, November 18, 2019 – Itiviti, a leading technology and service provider to financial institutions worldwide, today announced a partnership with Capital Market Solutions LLC. (CMS), a capital markets consultancy and solutions provider based in New York City. Under the partnership, Itiviti provides a complete regulatory reporting solution for the Securities and Exchange Commission (SEC) Rule 613 Consolidated Audit Trail (CAT), based on CMS’ Regulatory Surveillance & Monitoring System (RSMS).Available through Itiviti’s global organization, the new regulatory solution provides firms

Polygon AB (publ) announces the launch of its subsequent notes issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OR TO ANY PERSON LOCATED OR RESIDENT IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.Polygon AB (publ) reg. no. 556816-5855 (the "Company") announced on 6 November 2019 that it is soliciting consent from the Noteholders to obtain a waiver under the terms and conditions of the Notes dated 20 February 2018 (the "Terms and Conditions") (the "Consent Solicitation") in order to enable the Company to incur additional financial indebtedness (on a gross basis) (the "Proposal") and that it had

Arabia’s new service provides an alternative to owning: favourite tableware for a flat monthly fee

Fiskars GroupPress releaseNovember 18, 2019 Arabia’s new service provides an alternative to owning: favourite tableware for a flat monthly fee Arabia’s new, subscription-based tableware service allows customers to enjoy their favourite tableware for an affordable monthly fee. At the end of the subscription period, the tableware can be returned, purchased, or exchanged for another series. The service includes Arabia’s most popular tableware series, and the size of the tableware set is customisable. With people increasingly interested in borrowing, sharing and renting instead of

Addition: BrainCool AB's (publ) rights issue oversubscribed

This additional information concerns costs associated with the rights issue.The subscription period in BrainCool's rights issue of a maximum of SEK 40.1 million ended on November 13. A total of SEK 42 million was subscribed, a subscription rate of 105%, of which 80% was subscribed with preferential rights. Consequently, no guarantee commitments were needed. BrainCool is allocated SEK 40.1 million before costs associated with the rights issue, which are estimated to amount to SEK 4 million. CEO Martin Waleij comments; -        I would like to thank existing as well as new shareholders.

Knut Pedersen leaves as CEO of Catella

Catella AB's (publ) President and CEO Knut Pedersen has informed the Board that he wishes to leave his role as CEO. He will continue in his current role during the notice period of a maximum of 6 months and will leave the position as CEO at the latest in conjunction with the Annual General Meeting.Knut Pedersen has been CEO of Catella since January 1, 2014.“During his six years as CEO, Knut Pedersen has successfully developed Catella into a pan-European finance group in real estate and alternative investments. It is my belief that Knut still have a lot to add to Catella, why my wish is

Scandinavian ChemoTech and its CEO Mohan Frick participates and presents at the Emerging Medtech Summit in California, USA

Scandinavian ChemoTech and its CEO Mohan Frick has been selected to present its Tumour Specific Electroporation at the Emerging Medtech Summit in California, USA. An event bringing together the top strategists, investors, and innovators within the Medtech industry.The summit is a 3-day event where ChemoTech and other medical device companies will present their innovations to some of the largest medical device companies and institutional investors, such as: Medtronic, Johnson & Johnson, Boston Scientific, Wells Fargo, China Bio Group and many others. After ChemoTech’s unique platform for

Cantargia presents novel preclinical data on antibody CAN04 at PEGS Europe conference

Cantargia AB today announce that new preclinical data on the antibody CAN04 is presented at the 11th annual PEGS (Protein & Antibody Engineering Summit) Europe conference, Nov 18-22 in Lisbon, Portugal. CAN04 is in clinical development for cancer and is designed to enhance immune-mediated tumor cell killing. The new results show that similar design applied to CAN04 surrogate antibodies enhance antitumor effects in experimental cancer models and further support for the strategy chosen.Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP).

Stockholm International Film Festival’s Audience Award 2019 goes to Jojo Rabbit

After the 30th edition of the Stockholm International Film Festival ended on Sunday, we now have the pleasure to announce that the 2019 Audience Award goes to Jojo Rabbit by Taika Waititi. Photo from Jojo Rabbit.  Each year, the Stockholm International Film Festival invites the festival audience to select the winner of one of the most important awards of the festival – the Audience Award. The audience nominates their favourite film by voting on the festival’s website.  The audience have been able to vote for their favourites from this year’s 150 films on the festival website

CEO Hosni Teque-Omeirat acquires shares in the company

Hosni Teque-Omeirat, CEO, has acquired 1,050,000 shares in the company. The purchases were made on Nasdaq First North Growth Market at an average price of SEK 0.54.   For further information contact: Hosni Teque-OmeiratCEO+46 70 225 18 77 hosni@spectrumone.com Certified Adviser: Mangold Fondkommission AB (556585-1267) Box 55 691 102 15 Stockholm Telefon: +46 8 503 015 50 ca@mangold.se www.mangold.se   About TargetEveryone TargetEveryone is a MARTECH company, enabling our clients to streamline their 1-1 digital marketing, content and experiences within one

Medivir reports last patient recruited to the phase Ia study of MIV-818 in liver cancer patients and initial dose determined for phase Ib

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) reports today that the ninth and final patient was recruited to the phase Ia study of MIV-818 in patients with advanced liver cancer. Based on data from phase Ia, the initial dose of MIV-818 for the phase Ib study has been determined at 200 mg / week. The dosage is given as 40 mg / day for five days. The phase I study with MIV-818, evaluating safety, tolerability and pharmacokinetics, consists of two parts: Phase Ia is an interpatient study while phase Ib has a classic 3 + 3 intrapatient dose-escalating design. A recommended dose

Recipharm Offers to Acquire Consort Medical to Become a Leading Inhalation Company and Top Five Global CDMO Player

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PUBLICATION IS NEITHER AN OFFER TO BUY OR SELL NOR AN INVITATION TO TENDER OR OFFER TO BUY OR SELL SHARES. Read the whole press release Recipharm Offers to Acquire Consort Medical to Become a Leading Inhalation Company and Top Five Global CDMO Player  Contact informationThomas Eldered, CEO, telephone: +46 8 602 52 10Tobias

Bublar Group introduces Photorealistic Rendering on the Sayduck Platform - launches with Vallila Interior as first customer

Bublar Group’s subsidiary Sayduck launches its Photorealistic Rendering feature with Vallila Interior, a leading Finnish home textile company using the Sayduck Platform to provide better visualization of its products. The new feature allows anybody to create high-resolution, photorealistic images from 3D models. With the surge of online shopping and social media the value of visual content in marketing and sales has become more important than ever before. A major problem for manye-commerce companies is the process of generating images and visual elements that power up and create a

Therapeutic Hypothermia After Cardiac Arrest with Non-Shockable Rhythm (HYPERION) Shows Statistically Significant Results In Cardiac Arrest Patients Presented At AHA

The HYPERION study was published in New England Journal of Medicine (NEJM) on October 5, 2019, with a first simultaneous presentation at the ESICM meeting in Berlin, Germany. The study was also presented and discussed at the ReSS meeting, part of the American Heart meeting in Philadelphia on Nov 16, 2019 as a special presentation by the Principal Investigator (PI) of the trial, Dr. Jean-Baptiste Lascarrou. Although, BrainCool was not part of the study, the results will have a large impact on the development of the temperature management market. In 2013, Targeted Temperature Management (

Brighter accelerates the commercialization of Actiste and carries out a rights issue – without trading of subscription rights – of approximately SEK 192 million

The Board of Directors of Brighter AB (publ) ("Brighter" or "the Company") today, with the support of the issuance authorization granted at the Annual General Meeting on May 9, 2019, has decided to carry out a new issue of approximately SEK 192 million ("the Offer") to the Company's shareholders. The terms and conditions have been designed to benefit and reward the Company's shareholders. The Offer does not constitute a customary rights issue, and applies only to those who hold shares in the Company as of the record date of December 12, 2019. Subscription without the support of

Interim Report - January – September, 2019 Redsense Medical AB (publ)

Quarter 3, 2019, showed an increase in sales of 103% versus same period last year and is the strongest in the company’s history. The growth is driven by the US market.Financial Summary Third quarter, 1 July – 30 September 2019 Redsense Medical group · Sales amounted to 4 645 KSEK (2 286), with an increase of 103% compared to 2018. · Earnings before interest and taxes amounted to -590 KSEK (-970). Redsense Medical AB · Net sales amounted to 3 257 KSEK (1 871). · Earnings before interest and taxes amounted to -895 KSEK (-530). 1 January – 30 September 2019

Autoliv Introduces Airbag that Prevents Passengers from Colliding

(Ogden, Utah USA, November 18, 2019) – Autoliv Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in vehicle safety systems, today announced the development of a new front center airbag that is designed to save lives in side-impact crash situations. The airbag will be showcased at Autoliv’s Capital Markets Day held on November 19 at its technical center in Ogden, Utah. The head is one of the most frequently injured body regions in any road collision potentially resulting in devastating long-term consequences for the victim. For side collisions from the opposite side, the

There are no items matching the current filter
There are no more items matching the current filter
Back to top